Review



normal human serum standard  (Quidel)


Bioz Verified Symbol Quidel is a verified supplier
Bioz Manufacturer Symbol Quidel manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 95

    Structured Review

    Quidel normal human serum standard
    Normal Human Serum Standard, supplied by Quidel, used in various techniques. Bioz Stars score: 95/100, based on 232 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/normal+human+complement+standard/Normal+Human+Serum+-+Complement/pm41707327-64-0-12
    Average 95 stars, based on 232 article reviews
    normal human serum standard - by Bioz Stars, 2026-09
    95/100 stars

    Images

    Related Articles

    Incubation:

    Article Title: EMB ‐01, a Tetravalent Bispecific Antibody, Inducing Co‐Degradation of EGFR and c‐Met for Enhanced Anti‐Tumor Efficacy
    Article Snippet: Cytotoxicity was measured using the CytoTox‐ONE Homogeneous Membrane Integrity Assay (Promega, Cat G7891), following the manufacturer's instructions. .. HCC827 cells were incubated with serial dilutions of EMB‐01 or control antibody, followed by the addition of normal human serum complement (Quidel Corporation, Cat A113). .. After overnight incubation at 37°C, cell viability was assessed using the CellTiter‐Glo Luminescent Cell Viability Assay (Promega, Cat G7573).

    Article Title: Xenopus IgX informs engineering strategies of IgM and IgG hexamers
    Article Snippet: .. The RTX-Fcμ or RTX-Fcγ proteins were incubated with equal volumes of cell cultures (~20,000 cells) and 12% normal human serum complement (Quidel) sequentially and then transferred into a 96-microwell plate. .. After 8 hours of incubation at 37°C, 50 μl of CellTiter-Glo reagent (Promega, G7572) was added to each well and incubated for 10 min at room temperature.

    Article Title: Xenopus IgX informs engineering strategies of IgM and IgG hexamers.
    Article Snippet: .. The RTX- Fcμ or RTX- Fcγ proteins were incubated with equal volumes of cell cultures (~20,000 cells) and 12% normal human serum complement (Quidel) sequentially and then transferred into a 96- microwell plate. .. After 8 hours of incubation at 37°C, 50 μl of CellTiter- Glo reagent (Promega, G7572) was added to each well and incubated for 10 min at room temperature.

    Article Title: RNA particles comprising polysarcosine
    Article Snippet: Complement Activation In vitro C3a levels were determined using Human C3a EIA kit (Quidel). .. Briefly, LNPs and controls (positive (Cremophore El) and negative (1×PBS and EDTA (18 mM)) were incubated with Normal Human Serum Complement (NHS, Quidel) at a ratio of 20:80 (Specimen:NHS) for 1 h at 37° C. LNPs were tested at 5×, 1× and 0.02× based on a theoretical plasma concentration of 1 mg/kg mRNA dose. ..

    Article Title: EMB-01, a Tetravalent Bispecific Antibody, Inducing Co-Degradation of EGFR and c-Met for Enhanced Anti-Tumor Efficacy.
    Article Snippet: Cytotoxicity was measured using the CytoTox- ONE Homogeneous Membrane Integrity Assay (Promega, Cat G7891), following the manufacturer's instructions. nloaded from https://onlinelibrary.w iley.com /doi/10.1111/cas.70280, W iley O nline L ibrary on [20/12/2025]. .. See the T erm s and C onditions (https://onlinelibrary.w iley.com /term s-and-conditions) on W iley O nline L ibrary for rules of use; O A articles are governed by the applicable C reative C om m ons L icense 3Cancer Science, 2025 HCC827 cells were incubated with serial dilutions of EMB- 01 or control antibody, followed by the addition of normal human serum complement (Quidel Corporation, Cat A113). .. After overnight incubation at 37°C, cell viability was assessed using the CellTiter- Glo Luminescent Cell Viability Assay (Promega, Cat G7573).

    Control:

    Article Title: EMB ‐01, a Tetravalent Bispecific Antibody, Inducing Co‐Degradation of EGFR and c‐Met for Enhanced Anti‐Tumor Efficacy
    Article Snippet: Cytotoxicity was measured using the CytoTox‐ONE Homogeneous Membrane Integrity Assay (Promega, Cat G7891), following the manufacturer's instructions. .. HCC827 cells were incubated with serial dilutions of EMB‐01 or control antibody, followed by the addition of normal human serum complement (Quidel Corporation, Cat A113). .. After overnight incubation at 37°C, cell viability was assessed using the CellTiter‐Glo Luminescent Cell Viability Assay (Promega, Cat G7573).

    Article Title: EMB-01, a Tetravalent Bispecific Antibody, Inducing Co-Degradation of EGFR and c-Met for Enhanced Anti-Tumor Efficacy.
    Article Snippet: Cytotoxicity was measured using the CytoTox- ONE Homogeneous Membrane Integrity Assay (Promega, Cat G7891), following the manufacturer's instructions. nloaded from https://onlinelibrary.w iley.com /doi/10.1111/cas.70280, W iley O nline L ibrary on [20/12/2025]. .. See the T erm s and C onditions (https://onlinelibrary.w iley.com /term s-and-conditions) on W iley O nline L ibrary for rules of use; O A articles are governed by the applicable C reative C om m ons L icense 3Cancer Science, 2025 HCC827 cells were incubated with serial dilutions of EMB- 01 or control antibody, followed by the addition of normal human serum complement (Quidel Corporation, Cat A113). .. After overnight incubation at 37°C, cell viability was assessed using the CellTiter- Glo Luminescent Cell Viability Assay (Promega, Cat G7573).

    Clinical Proteomics:

    Article Title: RNA particles comprising polysarcosine
    Article Snippet: Complement Activation In vitro C3a levels were determined using Human C3a EIA kit (Quidel). .. Briefly, LNPs and controls (positive (Cremophore El) and negative (1×PBS and EDTA (18 mM)) were incubated with Normal Human Serum Complement (NHS, Quidel) at a ratio of 20:80 (Specimen:NHS) for 1 h at 37° C. LNPs were tested at 5×, 1× and 0.02× based on a theoretical plasma concentration of 1 mg/kg mRNA dose. ..

    Concentration Assay:

    Article Title: RNA particles comprising polysarcosine
    Article Snippet: Complement Activation In vitro C3a levels were determined using Human C3a EIA kit (Quidel). .. Briefly, LNPs and controls (positive (Cremophore El) and negative (1×PBS and EDTA (18 mM)) were incubated with Normal Human Serum Complement (NHS, Quidel) at a ratio of 20:80 (Specimen:NHS) for 1 h at 37° C. LNPs were tested at 5×, 1× and 0.02× based on a theoretical plasma concentration of 1 mg/kg mRNA dose. ..

    Article Title: Compositions and methods for using bispecific antibodies to bind complement and a target antigen
    Article Snippet: .. Bacteria were subsequently mixed with an equal volume of normal human serum (Quidel) or human serum depleted of a terminal complement protein (Quidel) such that the final concentration of serum was 50%. ..

    Bacteria:

    Article Title: Compositions and methods for using bispecific antibodies to bind complement and a target antigen
    Article Snippet: .. Bacteria were subsequently mixed with an equal volume of normal human serum (Quidel) or human serum depleted of a terminal complement protein (Quidel) such that the final concentration of serum was 50%. ..

    Transfection:

    Article Title: Anti-PD-L1 antibodies
    Article Snippet: TABLE 1 Commercial materials Materials Vendor Cat. PE mouse anti-human CD274 Ab eBioscience Cat. #12-5983-42 PE rat anti-mouse CD274 Ab eBioscience Cat. #12-4317-87 PE goat anti-mouse IgG Fc Abcam Cat. #ab98742 R-PE goat anti-human IgG Fc Jackson Immuno Cat. #109-115-098 Research PE goat anti-mouse IgG Fc Abcam Cat. #Ab98742 Human PD-L1, ECD, mFc tag Sino Biological Cat. #10084-H05H SA-PE eBioscience Cat. #12-4317-87 HRP goat anti-human IgG Fc Bethyl Cat. #A80-304P Ficoll-Paque TM PLUS GE Healthcare Cat. #17-1440-02 CD14 MicroBeads, human Milteny Cat. #130-050-201 Human CD4+ T Cell Enrichment kit STEMCELL Cat. #19052 Recombinant human GM-CSF Amoytop Cat. #S10980039 Biotech Recombinant human IL-4 R&D Cat. #204-IL-010 Standard recombinant human IFN-γ PeproTech Cat. #300-02 Human IFN-γ capture antibody Pierce Cat. #M700A Human IFN-γ detection antibody Pierce Cat. #M701B SA-HRP Invitrogen Cat. #SNN1004 Standard recombinant human IL-2 R&D Cat. #202-IL-010 Human IL-2 capture antibody R&D Cat. #MAB602 Human IL-2 detection antibody R&D Cat. #BAF202 Mouse IL-2 ELISA kit BD Cat. #2614KI CMV pp65 peptide Miltenyi Biotec Cat. #130-093-435 LPS Sigma Cat. #L5418 H3-thymidine PerkinElmer Cat. #NET027001MC MicroScint-20 PerkinElmer Cat. #6013621 Herceptin Roche Lot. .. #N3550 Human Serum Complement Quidel Cat. #A112 Cytotoxicity Detection Kit Roche Cat. #11644793001 CellTiter Glo Kit Promega Cat. #G7571 BT-474 cell line ATCC Cat. # HTB-20 Raji cell line ATCC Cat. #CCL-86 Lipofectamine TM 2000 Transfection Invitrogen Cat. #11668019 Reagent Ham's F-12K (Kaighn's) Medium Gibco Cat. #21127022 FreeStyle TM 293 Expression Medium Gibco Cat. #12338002 Fetal Bovine Serum HyClone Cat. #SV30087.03 Blasticidin Gibco Cat. #R21001 1.2 Material Code The codes or abbreviation for the materials including benchmark antibodies, the extracellular domains and the cells are summarized in Table 2. ..

    Expressing:

    Article Title: Anti-PD-L1 antibodies
    Article Snippet: TABLE 1 Commercial materials Materials Vendor Cat. PE mouse anti-human CD274 Ab eBioscience Cat. #12-5983-42 PE rat anti-mouse CD274 Ab eBioscience Cat. #12-4317-87 PE goat anti-mouse IgG Fc Abcam Cat. #ab98742 R-PE goat anti-human IgG Fc Jackson Immuno Cat. #109-115-098 Research PE goat anti-mouse IgG Fc Abcam Cat. #Ab98742 Human PD-L1, ECD, mFc tag Sino Biological Cat. #10084-H05H SA-PE eBioscience Cat. #12-4317-87 HRP goat anti-human IgG Fc Bethyl Cat. #A80-304P Ficoll-Paque TM PLUS GE Healthcare Cat. #17-1440-02 CD14 MicroBeads, human Milteny Cat. #130-050-201 Human CD4+ T Cell Enrichment kit STEMCELL Cat. #19052 Recombinant human GM-CSF Amoytop Cat. #S10980039 Biotech Recombinant human IL-4 R&D Cat. #204-IL-010 Standard recombinant human IFN-γ PeproTech Cat. #300-02 Human IFN-γ capture antibody Pierce Cat. #M700A Human IFN-γ detection antibody Pierce Cat. #M701B SA-HRP Invitrogen Cat. #SNN1004 Standard recombinant human IL-2 R&D Cat. #202-IL-010 Human IL-2 capture antibody R&D Cat. #MAB602 Human IL-2 detection antibody R&D Cat. #BAF202 Mouse IL-2 ELISA kit BD Cat. #2614KI CMV pp65 peptide Miltenyi Biotec Cat. #130-093-435 LPS Sigma Cat. #L5418 H3-thymidine PerkinElmer Cat. #NET027001MC MicroScint-20 PerkinElmer Cat. #6013621 Herceptin Roche Lot. .. #N3550 Human Serum Complement Quidel Cat. #A112 Cytotoxicity Detection Kit Roche Cat. #11644793001 CellTiter Glo Kit Promega Cat. #G7571 BT-474 cell line ATCC Cat. # HTB-20 Raji cell line ATCC Cat. #CCL-86 Lipofectamine TM 2000 Transfection Invitrogen Cat. #11668019 Reagent Ham's F-12K (Kaighn's) Medium Gibco Cat. #21127022 FreeStyle TM 293 Expression Medium Gibco Cat. #12338002 Fetal Bovine Serum HyClone Cat. #SV30087.03 Blasticidin Gibco Cat. #R21001 1.2 Material Code The codes or abbreviation for the materials including benchmark antibodies, the extracellular domains and the cells are summarized in Table 2. ..



    Similar Products

    95
    Quidel normal human serum standard
    Normal Human Serum Standard, supplied by Quidel, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/normal+human+complement+standard/Normal+Human+Serum+-+Complement/pm41707327-64-0-12
    Average 95 stars, based on 1 article reviews
    normal human serum standard - by Bioz Stars, 2026-09
    95/100 stars
      Buy from Supplier

    90
    Quidel normal human serum complement standard
    Normal Human Serum Complement Standard, supplied by Quidel, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/normal+human+complement+standard/normal+human+serum+complement+standard/pm38200010-378-3-12
    Average 90 stars, based on 1 article reviews
    normal human serum complement standard - by Bioz Stars, 2026-09
    90/100 stars
      Buy from Supplier

    96
    Quidel normal human complement
    ( A ) Anti-ACE2 IgM antibodies from patient CV-1 or control do not inhibit ACE2 activity. Positive and negative controls were ACE2 alone, and ACE2 plus ACE2 inhibitor, respectively (see ). ( B ) IgM antibodies to ACE2 activate <t>complement.</t> Purified IgMs from anti-ACE2 IgM–positive COVID-19 patients ( n = 8) and healthy controls ( n = 11) was used for C1q binding assays. Values are means from 2 independent experiments performed on different days. *** P < 0.0001, Mann-Whitney test. (C–G) Anti-ACE2 IgM affects the pulmonary endothelium. ( C ) Phase image of a pulmonary microvessel (top). Fluorescence images of microvessels exposed to anti-ACE2–negative IgM (HC) or anti-ACE2–positive IgM (CV) after perfusion with 10 kDa dextran (lower). Representative images across n = 3 to 6 independent experiments for each IgM condition are shown. ( D ) ACE2 and CD31 microvessel staining following 24-hour perfusion with IFN-α/γ. Representative images across n = 3 independent experiments are shown. ( E ) C3c staining after perfusion with IFN and anti-ACE2–positive or control IgM (3.33 μg/mL). Representative images across n = 3 independent experiments are shown. ( F ) Permeability of microvessels perfused with IFN and anti-ACE2–positive IgM (CV) or anti-ACE2 negative IgM (HC) (100 μg/mL). D.L., detection limit. A linear mixed effects model was used to test the effect of anti-ACE2–positive IgM on permeability. n = 3 to 5 for each IgM condition; each dot represents an independent replicate. ( G ) Inhibition of microvessel permeability to 10 kDa dextran in response to anti-ACE2 IgM is IFN dependent. Low CV-1: 3.33 μg/mL; affinity-purified anti-ACE2 IgM: 100 ng/mL. To compare each condition to control, a Kruskal-Wallis test followed by Dunn’s multiple-comparison test was performed. n = 4 to 6 for each IgM condition; each dot represents an independent replicate.
    Normal Human Complement, supplied by Quidel, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/normal+human+complement+standard/Human+Complement+Standard/pmc09090251-226-26-29
    Average 96 stars, based on 1 article reviews
    normal human complement - by Bioz Stars, 2026-09
    96/100 stars
      Buy from Supplier

    96
    Quidel normal human complement standard
    a Map of <t>complement-mediated</t> bactericidal activity. b The proportion of gut bacteria after 16s rRNA analyses of colon contents in normal CFD fl/fl pvillin-cre w (WT) and CFD fl/fl pvillin-cre T (CFDKO) mice (pooled samples from six mice). Also see Fig. . c The proportion of gut bacteria after 16s rRNA analyses in CFD fl/fl pvillin-cre w (WT) and CFD fl/fl pvillin-cre T (CFDKO) mice after 2% DSS. Also see Fig. . d The proportion of E. coli (Escherichia-Shigella) in CFD fl/fl pvillin-cre w (WT) and CFD fl/fl pvillin-cre T (CFDKO) mice after 2% DSS ( n = 5). Also see Fig. S3C. e Flow cytometry of feces bacteria after staining using anti-LPS antibodies in CFD fl/fl pvillin-cre w (WT) and CFD fl/fl pvillin-cre T (CDKO) mice after 2% DSS. f QPCR of colonic content (upper) and colonic tissues (lower) in CFD fl/fl pvillin-cre w (WT) and CFD fl/fl pvillin-cre T (CFDKO) mice after 2% DSS ( n = 6). g FISH of E. coli in the gut tissues of CFD fl/fl pvillin-cre w (WT) and CFD fl/fl pvillin-cre T (CFDKO) mice after 2% DSS. One representative from six mice. Scale bar, 40 μM; Scale bar in bottom panel, 5 μM. Two side student’s t test in e and f ; * P < 0.05; ** P < 0.01; *** P < 0.001; NS no significance.
    Normal Human Complement Standard, supplied by Quidel, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/normal+human+complement+standard/Human+Complement+Standard/pmc07468294-273-17-21
    Average 96 stars, based on 1 article reviews
    normal human complement standard - by Bioz Stars, 2026-09
    96/100 stars
      Buy from Supplier

    Image Search Results


    ( A ) Anti-ACE2 IgM antibodies from patient CV-1 or control do not inhibit ACE2 activity. Positive and negative controls were ACE2 alone, and ACE2 plus ACE2 inhibitor, respectively (see ). ( B ) IgM antibodies to ACE2 activate complement. Purified IgMs from anti-ACE2 IgM–positive COVID-19 patients ( n = 8) and healthy controls ( n = 11) was used for C1q binding assays. Values are means from 2 independent experiments performed on different days. *** P < 0.0001, Mann-Whitney test. (C–G) Anti-ACE2 IgM affects the pulmonary endothelium. ( C ) Phase image of a pulmonary microvessel (top). Fluorescence images of microvessels exposed to anti-ACE2–negative IgM (HC) or anti-ACE2–positive IgM (CV) after perfusion with 10 kDa dextran (lower). Representative images across n = 3 to 6 independent experiments for each IgM condition are shown. ( D ) ACE2 and CD31 microvessel staining following 24-hour perfusion with IFN-α/γ. Representative images across n = 3 independent experiments are shown. ( E ) C3c staining after perfusion with IFN and anti-ACE2–positive or control IgM (3.33 μg/mL). Representative images across n = 3 independent experiments are shown. ( F ) Permeability of microvessels perfused with IFN and anti-ACE2–positive IgM (CV) or anti-ACE2 negative IgM (HC) (100 μg/mL). D.L., detection limit. A linear mixed effects model was used to test the effect of anti-ACE2–positive IgM on permeability. n = 3 to 5 for each IgM condition; each dot represents an independent replicate. ( G ) Inhibition of microvessel permeability to 10 kDa dextran in response to anti-ACE2 IgM is IFN dependent. Low CV-1: 3.33 μg/mL; affinity-purified anti-ACE2 IgM: 100 ng/mL. To compare each condition to control, a Kruskal-Wallis test followed by Dunn’s multiple-comparison test was performed. n = 4 to 6 for each IgM condition; each dot represents an independent replicate.

    Journal: JCI Insight

    Article Title: IgM anti-ACE2 autoantibodies in severe COVID-19 activate complement and perturb vascular endothelial function

    doi: 10.1172/jci.insight.158362

    Figure Lengend Snippet: ( A ) Anti-ACE2 IgM antibodies from patient CV-1 or control do not inhibit ACE2 activity. Positive and negative controls were ACE2 alone, and ACE2 plus ACE2 inhibitor, respectively (see ). ( B ) IgM antibodies to ACE2 activate complement. Purified IgMs from anti-ACE2 IgM–positive COVID-19 patients ( n = 8) and healthy controls ( n = 11) was used for C1q binding assays. Values are means from 2 independent experiments performed on different days. *** P < 0.0001, Mann-Whitney test. (C–G) Anti-ACE2 IgM affects the pulmonary endothelium. ( C ) Phase image of a pulmonary microvessel (top). Fluorescence images of microvessels exposed to anti-ACE2–negative IgM (HC) or anti-ACE2–positive IgM (CV) after perfusion with 10 kDa dextran (lower). Representative images across n = 3 to 6 independent experiments for each IgM condition are shown. ( D ) ACE2 and CD31 microvessel staining following 24-hour perfusion with IFN-α/γ. Representative images across n = 3 independent experiments are shown. ( E ) C3c staining after perfusion with IFN and anti-ACE2–positive or control IgM (3.33 μg/mL). Representative images across n = 3 independent experiments are shown. ( F ) Permeability of microvessels perfused with IFN and anti-ACE2–positive IgM (CV) or anti-ACE2 negative IgM (HC) (100 μg/mL). D.L., detection limit. A linear mixed effects model was used to test the effect of anti-ACE2–positive IgM on permeability. n = 3 to 5 for each IgM condition; each dot represents an independent replicate. ( G ) Inhibition of microvessel permeability to 10 kDa dextran in response to anti-ACE2 IgM is IFN dependent. Low CV-1: 3.33 μg/mL; affinity-purified anti-ACE2 IgM: 100 ng/mL. To compare each condition to control, a Kruskal-Wallis test followed by Dunn’s multiple-comparison test was performed. n = 4 to 6 for each IgM condition; each dot represents an independent replicate.

    Article Snippet: Seventy-two hours after initial cell seeding (24 hours after incubation with IFNs), microvessels were treated with 100 μg/mL patient IgM in EC medium supplemented with 10% normal human complement (Quidel) for 30 minutes under low-flow conditions (~0.3 dyne/cm 2 ).

    Techniques: Control, Activity Assay, Purification, Binding Assay, MANN-WHITNEY, Fluorescence, Staining, Permeability, Inhibition, Affinity Purification, Comparison

    a Map of complement-mediated bactericidal activity. b The proportion of gut bacteria after 16s rRNA analyses of colon contents in normal CFD fl/fl pvillin-cre w (WT) and CFD fl/fl pvillin-cre T (CFDKO) mice (pooled samples from six mice). Also see Fig. . c The proportion of gut bacteria after 16s rRNA analyses in CFD fl/fl pvillin-cre w (WT) and CFD fl/fl pvillin-cre T (CFDKO) mice after 2% DSS. Also see Fig. . d The proportion of E. coli (Escherichia-Shigella) in CFD fl/fl pvillin-cre w (WT) and CFD fl/fl pvillin-cre T (CFDKO) mice after 2% DSS ( n = 5). Also see Fig. S3C. e Flow cytometry of feces bacteria after staining using anti-LPS antibodies in CFD fl/fl pvillin-cre w (WT) and CFD fl/fl pvillin-cre T (CDKO) mice after 2% DSS. f QPCR of colonic content (upper) and colonic tissues (lower) in CFD fl/fl pvillin-cre w (WT) and CFD fl/fl pvillin-cre T (CFDKO) mice after 2% DSS ( n = 6). g FISH of E. coli in the gut tissues of CFD fl/fl pvillin-cre w (WT) and CFD fl/fl pvillin-cre T (CFDKO) mice after 2% DSS. One representative from six mice. Scale bar, 40 μM; Scale bar in bottom panel, 5 μM. Two side student’s t test in e and f ; * P < 0.05; ** P < 0.01; *** P < 0.001; NS no significance.

    Journal: Communications Biology

    Article Title: Reg4 and complement factor D prevent the overgrowth of E. coli in the mouse gut

    doi: 10.1038/s42003-020-01219-2

    Figure Lengend Snippet: a Map of complement-mediated bactericidal activity. b The proportion of gut bacteria after 16s rRNA analyses of colon contents in normal CFD fl/fl pvillin-cre w (WT) and CFD fl/fl pvillin-cre T (CFDKO) mice (pooled samples from six mice). Also see Fig. . c The proportion of gut bacteria after 16s rRNA analyses in CFD fl/fl pvillin-cre w (WT) and CFD fl/fl pvillin-cre T (CFDKO) mice after 2% DSS. Also see Fig. . d The proportion of E. coli (Escherichia-Shigella) in CFD fl/fl pvillin-cre w (WT) and CFD fl/fl pvillin-cre T (CFDKO) mice after 2% DSS ( n = 5). Also see Fig. S3C. e Flow cytometry of feces bacteria after staining using anti-LPS antibodies in CFD fl/fl pvillin-cre w (WT) and CFD fl/fl pvillin-cre T (CDKO) mice after 2% DSS. f QPCR of colonic content (upper) and colonic tissues (lower) in CFD fl/fl pvillin-cre w (WT) and CFD fl/fl pvillin-cre T (CFDKO) mice after 2% DSS ( n = 6). g FISH of E. coli in the gut tissues of CFD fl/fl pvillin-cre w (WT) and CFD fl/fl pvillin-cre T (CFDKO) mice after 2% DSS. One representative from six mice. Scale bar, 40 μM; Scale bar in bottom panel, 5 μM. Two side student’s t test in e and f ; * P < 0.05; ** P < 0.01; *** P < 0.001; NS no significance.

    Article Snippet: 5 × 10 5 or 1 × 10 6 CFU was added into PBS that contains 10% Normal Human Complement Standard (Quidel), C1q-depleted serum (Quidel) or C3 depleted and CFD depleted serum (Quidel).

    Techniques: Activity Assay, Bacteria, Flow Cytometry, Staining

    a E. coli clones in the normal human sera (N. Sera, Quidel), C3deficient sera (C3defi, Quidel), C1 deficient sera (C1 defi, Quidel) and inactive sera at different time points. *C3deficint sera vs normal sera. b E. coli clones in the normal sera (N. Sera, Quidel), CFD-deficient sera (CFD defi, Quidel) inactive sera at different time points. *CFD-deficient sera vs normal sera. c E. coli clones in the normal human sera after adding LPS (containing mannose), mannose or peptidoglycan. *LPS vs normal sera. d E. coli clones in the normal human sera after adding rReg4, rREG4 or mutated rREG4. *Reg4 vs normal sera. Only mrReg4 and only hrREG4, E.coli clones in inactive complement serum after adding mrReg4 or hrREG4. e E. coli clones in the normal human sera after adding different concentrations of rReg4. f E. coli clones in the normal human sera (N. sera) or CFD-deficient (CFD defi) sera after adding rReg4 (N. sera/rReg4 or CFDdefi/rReg4). *Normal sera/Reg4 vs normal sera. g E. coli clones in the normal human sera after adding rREG4, IgA or IgA+REG4. *IgA+Reg4 vs Reg4. Around 5 × 10 5 in a – c or 1 × 10 6 in d – g E. coli CFUs were added into 1 ml 10% sera. Bacterial suspension were diluted and plated on MacConkey agar plates. Plates were incubated overnight at 37 °C, and CFU were counted. Analysis of variance test used in a – g . * P < 0.05; ** P < 0.01; *** P < 0.001; NS no significance. One representative of three independent experiments.

    Journal: Communications Biology

    Article Title: Reg4 and complement factor D prevent the overgrowth of E. coli in the mouse gut

    doi: 10.1038/s42003-020-01219-2

    Figure Lengend Snippet: a E. coli clones in the normal human sera (N. Sera, Quidel), C3deficient sera (C3defi, Quidel), C1 deficient sera (C1 defi, Quidel) and inactive sera at different time points. *C3deficint sera vs normal sera. b E. coli clones in the normal sera (N. Sera, Quidel), CFD-deficient sera (CFD defi, Quidel) inactive sera at different time points. *CFD-deficient sera vs normal sera. c E. coli clones in the normal human sera after adding LPS (containing mannose), mannose or peptidoglycan. *LPS vs normal sera. d E. coli clones in the normal human sera after adding rReg4, rREG4 or mutated rREG4. *Reg4 vs normal sera. Only mrReg4 and only hrREG4, E.coli clones in inactive complement serum after adding mrReg4 or hrREG4. e E. coli clones in the normal human sera after adding different concentrations of rReg4. f E. coli clones in the normal human sera (N. sera) or CFD-deficient (CFD defi) sera after adding rReg4 (N. sera/rReg4 or CFDdefi/rReg4). *Normal sera/Reg4 vs normal sera. g E. coli clones in the normal human sera after adding rREG4, IgA or IgA+REG4. *IgA+Reg4 vs Reg4. Around 5 × 10 5 in a – c or 1 × 10 6 in d – g E. coli CFUs were added into 1 ml 10% sera. Bacterial suspension were diluted and plated on MacConkey agar plates. Plates were incubated overnight at 37 °C, and CFU were counted. Analysis of variance test used in a – g . * P < 0.05; ** P < 0.01; *** P < 0.001; NS no significance. One representative of three independent experiments.

    Article Snippet: 5 × 10 5 or 1 × 10 6 CFU was added into PBS that contains 10% Normal Human Complement Standard (Quidel), C1q-depleted serum (Quidel) or C3 depleted and CFD depleted serum (Quidel).

    Techniques: Clone Assay, Suspension, Incubation

    a Immunostaining of C3b, C5-9, Reg4, IgA, MASP1/3 and MASP2 on GFP-labeled E. coli in 2% DSS-treated GFP-labeled E. coli infused CFD fl/fl pvillin-cre T (CFDKO/0160) mice (Left) and statistic analyses (right, three images/slide, three slides/mouse, n = 6). Scale bar, 40 μM. No, number; Iso, isotypic antibod. b Flow cytometry of Reg4, IgA, MASP1/3 and MASP2 on the GFP-labeled E. coli in untreated GFP-labeled E. coli infused CFD fl/fl pvillin-cre w (WT) and CFD fl/fl pvillin-cre T (CFDKO) mice and statistic analyses ( n = 3). c ELISA for detecting binding of Reg4 with LPS (left), Reg4 with IgA (middle) or IgA with LPS (right) in different concentration of Reg4 (left and middle) or IgA (right) coated plates d ELISA of C3 in different concentration of Reg4 (left) or IgA (right) with LPS coated plates. For complement resources, 5% normal human sera were added. e ELISA of C3b in the LPS, Reg4, IgA, LPS + Reg4 (LPS/Reg4), LPS + IgA (LPS/IgA), Reg4+IgA (Reg4/IgA) and LPS + Reg4+IgA (LPS/Reg4/IgA) coated plates. For complement resources, 5% normal human sera were added. Mann–Whitney U test in a ; Two side student’s t test in b ; ANOVA plus post-Bonferroni analysis in e ; Analysis of variance test in c and d . * P < 0.05; ** P < 0.01; *** P < 0.001; NS no significance. In c – e , one representative of three independent experiments.

    Journal: Communications Biology

    Article Title: Reg4 and complement factor D prevent the overgrowth of E. coli in the mouse gut

    doi: 10.1038/s42003-020-01219-2

    Figure Lengend Snippet: a Immunostaining of C3b, C5-9, Reg4, IgA, MASP1/3 and MASP2 on GFP-labeled E. coli in 2% DSS-treated GFP-labeled E. coli infused CFD fl/fl pvillin-cre T (CFDKO/0160) mice (Left) and statistic analyses (right, three images/slide, three slides/mouse, n = 6). Scale bar, 40 μM. No, number; Iso, isotypic antibod. b Flow cytometry of Reg4, IgA, MASP1/3 and MASP2 on the GFP-labeled E. coli in untreated GFP-labeled E. coli infused CFD fl/fl pvillin-cre w (WT) and CFD fl/fl pvillin-cre T (CFDKO) mice and statistic analyses ( n = 3). c ELISA for detecting binding of Reg4 with LPS (left), Reg4 with IgA (middle) or IgA with LPS (right) in different concentration of Reg4 (left and middle) or IgA (right) coated plates d ELISA of C3 in different concentration of Reg4 (left) or IgA (right) with LPS coated plates. For complement resources, 5% normal human sera were added. e ELISA of C3b in the LPS, Reg4, IgA, LPS + Reg4 (LPS/Reg4), LPS + IgA (LPS/IgA), Reg4+IgA (Reg4/IgA) and LPS + Reg4+IgA (LPS/Reg4/IgA) coated plates. For complement resources, 5% normal human sera were added. Mann–Whitney U test in a ; Two side student’s t test in b ; ANOVA plus post-Bonferroni analysis in e ; Analysis of variance test in c and d . * P < 0.05; ** P < 0.01; *** P < 0.001; NS no significance. In c – e , one representative of three independent experiments.

    Article Snippet: 5 × 10 5 or 1 × 10 6 CFU was added into PBS that contains 10% Normal Human Complement Standard (Quidel), C1q-depleted serum (Quidel) or C3 depleted and CFD depleted serum (Quidel).

    Techniques: Immunostaining, Labeling, Flow Cytometry, Enzyme-linked Immunosorbent Assay, Binding Assay, Concentration Assay, MANN-WHITNEY